BioPharmSignal logoBioPharmSignal

Biotech News

Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days

Harmony Biosciences (HRMY)Harmony BiosciencesConference / presentation

PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 trials of HBS-301, including ONSTRIDE-1 in narcolepsy and ONSTRIDE-2 in idiopathic hypersomnia.

Related news

HRMYHarmony Biosciences2026-09-03 12:05 EST

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

HRMYHarmony Biosciences2026-08-27 12:05 EST

Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference

NBIXNeurocrine Biosciences2026-09-30 12:30 EST

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference

NBIXNeurocrine Biosciences2026-09-02 20:01 EST

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

KTTAPasithea Therapeutics2026-07-21 11:00 EST

Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026

XENEXenon2026-09-03 20:01 EST

Xenon to Present at Wells Fargo Healthcare Conference

CLNNClene Inc.2026-08-17 12:30 EST

Clene to Present at the Emerging Growth Conference

CLNNClene Inc.2026-07-29 12:30 EST

Clene to Present at The Canaccord 46th Annual Growth Conference

ABOSAcumen Pharmaceuticals2026-07-07 11:30 EST

Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

GANXGain Therapeutics2026-09-29 21:50 EST

Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders

View all latest news

Harmony Biosciences

Sleep and Neurologic Disorders Harmony Biosciences develops and commercializes medicines for rare neurologic diseases. Its business is anchored by therapies that regulate wakefulness and sleep-wake signaling. WAKIX Franchise WAKIX, or pitolisant, is a histamine H3 receptor antagonist/inverse agonist used in narcolepsy and is the...

Recent company news

HRMYHarmony Biosciences2026-10-01 12:05 EST

Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days

HRMYHarmony Biosciences2026-09-22 12:30 EST

Harmony Biosciences Recognizes World Narcolepsy Day 2026, Reflecting on Nearly a Decade of Commitment to the Sleep Community

HRMYHarmony Biosciences2026-09-03 12:05 EST

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

HRMYHarmony Biosciences2026-08-27 12:05 EST

Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference

HRMYHarmony Biosciences2026-08-06 12:05 EST

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

Stock data

Close
39.57 USD
Market cap
1.79B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States